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Background: The disease course of patients with diffuse low-grade glioma is notoriously unpredictable. Temporal
and spatially distinct samples may provide insight into the evolution of clinically relevant copy number aberrations
(CNAs). The purpose of this study is to identify CNAs that are indicative of aggressive tumor behavior and can
thereby complement the prognostically favorable 1p/19q co-deletion.
Results: Genome-wide, 50 base pair single-end sequencing was performed to detect CNAs in a clinically
well-characterized cohort of 98 formalin-fixed paraffin-embedded low-grade gliomas. CNAs are correlated with
overall survival as an endpoint. Seventy-five additional samples from spatially distinct regions and paired recurrent
tumors of the discovery cohort were analyzed to interrogate the intratumoral heterogeneity and spatial evolution.
Loss of 10q25.2-qter is a frequent subclonal event and significantly correlates with an unfavorable prognosis. A
significant correlation is furthermore observed in a validation set of 126 and confirmation set of 184 patients. Loss
of 10q25.2-qter arises in a longitudinal manner in paired recurrent tumor specimens, whereas the prognostically
favorable 1p/19q co-deletion is the only CNA that is stable across spatial regions and recurrent tumors.
Conclusions: CNAs in low-grade gliomas display extensive intratumoral heterogeneity. Distal loss of 10q is a late
onset event and a marker for reduced overall survival in low-grade glioma patients. Intratumoral heterogeneity and
higher frequencies of distal 10q loss in recurrences suggest this event is involved in outgrowth to the recurrent
tumor.Background
Diffuse low-grade gliomas (LGGs) are regarded as slow
growing malignant brain tumors and patients can live up
to 30 years with this disease. In a subset of patients the
tumor exerts a more aggressive behavior and survival
can be as short as two years [1]. Personalized timing of
postoperative treatment is crucial to forestall progression
in the latter group whilst preventing long-term side-effects
for patients with more favorable prospects [2]. The disease* Correspondence: b.ylstra@vumc.nl
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unless otherwise stated.course of patients with LGGs is correlated with gene
mutations, such as in p53 and IDH1, hypermethylation
of MGMT as well as chromosomal copy number aberra-
tions (CNAs). Regarding the latter, assessment of com-
bined loss of 1p and 19q currently is implemented in
routine clinical care in specific glioma subgroups given
its favorable prognostic and predictive value [3,4]. Other
CNAs, such as losses of chromosomes 10 and 11p, have
been reported to be prognostically unfavorable, but have
not been introduced into clinical practice yet, possibly
due the limited number of samples included in the stud-
ies and/or lack of validation [5-7]. Unfavorable events
might go undetected as a consequence of intratumoralral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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if they are only present in the more malignant subclones
of LGGs that seed outgrowth of a recurrent tumor [9],
thereby promoting a large extent of resection. As
current knowledge on the temporal and spatial evolu-
tion of CNAs in LGGs is limited, we evaluated CNAs
in a clinically and histologically representative cohort
of formalin-fixed archival samples using shallow whole
genome sequencing (shallow WGS). We demonstrate
that loss of part or whole chromosome 10q is prognos-
tically unfavorable and often present in a subclonal
manner.Results
Clinical and histological data
We studied 173 formalin-fixed paraffin-embedded (FFPE)
samples from 98 LGG patients, including spatially distinct
regions and paired recurrent tumors, by shallow WGS.
Patients had either deceased or had passed the median
survival time of six years for LGGs. Other inclusion cri-
teria and patient characteristics of this discovery cohort
are summarized in Figure 1 and Table 1. Age at diagno-
sis, overall survival and postoperative treatment (typeFigure 1 Accrual of samples and clinical data of the discovery cohort
connected with vertical arrows. Reasons for exclusion of samples are listed
number below each box represents the number of patients. Boxes below t
spatially distinct regions of LGGs. AII, astrocytoma; H&E, hematoxylin and eoand timing) varied extensively between patients, but not
between the five participating hospitals, which contrib-
uted nearly equal numbers of cases. Comparison of
overall survival between patients treated immediately
after surgery and those for whom postoperative treat-
ment was withheld did not reveal statistically significant
differences. Characteristics of the LGG patients of the
French validation (n =126) [5] and confirmation cohorts
(n =184), the latter from publicly available data from
The Cancer Genome Atlas (TCGA) [10], are also listed
in Table 1. Due to the retrospective character of this
study, the cohorts are not matched; there is considerable
variation in duration of follow-up and the percentage of
patients deceased and for which information on overall
survival is available, as well as in the distribution of histo-
logical subgroups.Copy number detection by shallow WGS in LGGs
To obtain genome-wide copy numbers from the FFPE
samples of our discovery cohort, we evaluated the use of
shallow WGS. First, for sample LGG284 a paired-end
100 (PE100) sequence run was performed. Copy number
profiles were produced by counting the unique sequence. Samples were selected based on criteria listed in the boxes
in boxes in the right panel, connected with horizontal arrows. The
he dotted line list criteria for collection of recurrent tumors and
sin; OII, oligodendroglioma; OAII, oligoastrocytoma.
Table 1 Characteristics of diffuse low-grade glioma
patients in the discovery, validation and confirmation
cohorts
Variable Dutch
discovery
cohort
(n =98)
French
validation
cohort
(n =126)
TCGA
confirmation
cohort
(n =184)
Gender
Female 50 (51%) 59 (47%) 93 (51%)
Age at diagnosis (years)
Mean 40.3 39.8 40.8
Median 39.6 39.4 39
Range (21-83) (18-76) (14-87)
Duration of follow-up of patients
still alive at last evaluation (months)
Mean 133.6 39.6 23.7
Median 129.0 30.9 10.7
Range 72-288 1-187 1-185
Patients deceased 46 (47%) 32 (25%) 18 (10%)
Overall survival of patients
deceased at last evaluation
(months)
Mean 89 48.6 63.5
Median 149.0 51.8 65.6
Range 1-361 0.1-98 1.2-132.6
Histological subtypes
Oligodendroglioma 43 (43%) 53 (42%) 87 (47%)
Astrocytoma 42 (42%) 23 (18%) 40 (22%)
Oligoastrocytoma 15 (15%) 50 (40%) 57 (31%)
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both ends (PE100 in Figure S1A in Additional file 1), the
single 100 bp read from one end (SR100 in Figure S1B in
Additional file 1) and the trimmed first single 50 bp read
from the same end (SR50 in Figure S1C in Additional file 1).
The noise (measured as variance) of the different profiles
is very similar and CNAs observed are indistinguishable
from each other, which implies that the uniqueness of the
50 bp sequence tags suffices to infer copy number levels,
and longer reads are not necessary. Array comparative
genomic hybridization (array CGH) was performed on the
same DNA sample, which confirmed the CNAs detected
(Figure S1D in Additional file 1). For an additional eight
samples both 50 bp single-read (SR50) shallow WGS and
array CGH were applied as technical validation. Shallow
WGS and array analysis invariably yielded the same CNA
profiles (Figure S2 in Additional file 1). Based on this in-
formation, all subsequent analyses were performed using
50 bp single-read (SR50) shallow WGS since it is more
cost-effective and allows the use of samples with short
DNA fragments, which are frequently obtained with FFPE
materials. The most frequent CNAs, detected in morethan 10% of cases, are whole or partial loss of chromo-
somal arms 9p, 10q, 12p, 13 and 14, as well as gain of
chromosomal arms 7q, 8q, 10p and 11q. The most fre-
quent CNAs in this cohort are co-deletion of 1p and
19q often accompanied by loss of whole chromosome 4,
all commensurate with previous reports [11] (Figure 2).
The prognostic value of CNAs in discovery, validation and
confirmation cohorts
Association of survival with CNAs detected in the dis-
covery cohort was tested. In addition to the known
prognostically favorable 1p/19q co-deletion, five further
chromosomal losses at chromosomes 9p, distal 10q,
11p, 13q, and 22q presented with statistical significance
(Table 2). No associations were observed with gains.
Significant regions were verified in the French validation
cohort of 126 diffuse LGG patients (Table 1). Loss of
distal 10q was an unfavorable CNA in both cohorts,
whereas losses of chromosomal regions at 9p, 11p, 13q
and 22q were not substantiated in the validation cohort
(Table 2). In the discovery cohort, median overall sur-
vival for patients with or without loss of whole or distal
10q was respectively 6.6 years versus 16.7 years (18/98,
P-value =0.009). The size of chromosome 10 deletion
varies from whole chromosome loss (5/18) to 22.5 Mbp
distal loss (10q25.2- 10qter). An association between
loss of this region with overall survival was finally tested
in the TCGA dataset of LGG. Despite the limited num-
ber of patients deceased in this cohort (Table 1), a sig-
nificant association with overall survival was observed
(P-value =0.0018) (Figure 3), which confirms that distal
10q is a prognostically unfavorable chromosomal aberration.
In the discovery cohort, absence of IDH1 or IDH2muta-
tion (11/98) was overrepresented in patients with distal
10q loss (7/11; five with whole chromosome 10 loss and
two with distal 10q loss). After splitting the cohort by IDH
status, a trend for distal 10q loss was observed; in the IDH
mutant subgroup (n =87) the log rank test for loss of 10q
(n =11) yielded a P-value of 0.077, and in the IDH wild-
type subgroup (n =11), a similar P-value of 0.068 was
yielded through the test for distal loss of 10q (n =7).
Co-deletion of 1p/19q was predominantly detected in
LGGs with oligodendroglial histological features while loss
of distal 10q was more frequently identified in astrocytic
LGGs. However, there was no one-to-one relationship be-
tween histological features and these CNAs (Figure 2).
Co-deletion of 1p/19q combined with distal 10q loss was
observed in three LGGs of the discovery cohort and four
LGGs of the validation cohort (all with oligodendroglial
features) and none in the confirmation cohort. This lim-
ited number of patients does not allow for proper statis-
tical survival analysis, but median survival of the patients
in these cohorts combined (13.4 years) suggests that loss
of 1p/19q and distal 10q counteracts overall survival.
19
20
22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
ch
ro
m
os
om
es
samples
normal
loss
gain
copy number
OII
OAII
AII
histology
Figure 2 Unsupervised clustering of CNAs in the discovery cohort. Histological subtypes and patients are color-coded on the x-axis and
chromosomes are ordered on the y-axis, 1 to 22 from bottom to top. Shades of green enable visualization of individual chromosomal arms, their
size varying by the number of regions. Hence, a chromosomal arm with many breakpoints based on CNAs is depicted as larger compared with
one with fewer breakpoints. Red, copy number loss; blue, copy number gain; black, no CNA. OII, oligodendroglioma; OAII, oligoastrocytoma;
AII, astrocytoma.
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tients with a favorable (1p/19q co-deletion), unfavorable
(distal 10q loss), or intermediate (both) prognosis in all
three cohorts (Figure 3A,B,C). In the discovery cohort,
hazard ratios of 1p/19q co-deletion without distal 10q loss
and of distal 10q loss without 1p/19q co-deletion were
0.30 (95% confidence interval 0.15 to 0.58), and 2.91 (95%
confidence interval 1.53 to 5.55), respectively (Table 3).Table 2 Prognostically unfavorable chromosomal regions of l
Chromosome Start End Cytoband Disc
coh
9 24450001 28650000 9p21.3-21.1
10 112950001 135435000 10q25.2-qter
11 195001 14250000 11p15.5-15.2
13 19500001 92550000 13q12.1-31.3
22 34350001 51180000 22q12.3-13.33
Frequency and P-value in discovery and validation cohorts calculated by log rank te
Bonferroni, respectively. Positions according to GRCh37/hg19.Intratumoral heterogeneity of CNAs in LGGs
In addition to the above-mentioned CNAs detected in
single samples, we studied intratumoral heterogeneity by
shallow WGS of multiple, spatially distinct regions ob-
tained during the same surgery. Among other CNAs, dis-
tribution of 10q loss was assessed, illustrated for LGG240
in Figure 4 (more examples are provided in Additional file 2).
In the original chromosomal profile of LGG240, marginaloss in diffuse low-grade gliomas
overy
ort (%)
Validation
cohort (%)
Discovery cohort Validation cohort
(P-value) (P-value)
21 7 0.039 1
18 10 0.009 0.041
13 15 0.0006 1
17 13 0.0001 1
11 8 0.000004 1
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Figure 3 Kaplan Meier plots for distal 10q loss and 1p/19q co-deletion in (A) discovery, (B) validation and (C) confirmation cohorts. The
dark blue line indicates loss of distal 10q without 1p/19q co-deletion versus the rest of the cohort (n =15, P-value =0.001 in (A), n =8, P-value =0.018 in
(B), and n =14, P-value =0.0018 in (C). The green line indicates 1p/19q co-deletion without distal loss of 10q (n =38, P-value =0.0001 in (A), n =41,
P-value =0.0005 in (B), and n =47, P-value =0.74 in (C). The light blue line indicates 10q loss and 1p/19q co-deletion (n =3, P-value =0.39 in (A), n =4,
P-value =0.94 in (B), and n =0 in (C). The grey line indicates neither 10q deletion nor 1p/19q co-deletion (n =42 in (A), n =73 in (B), and n =123 in (C).
The y-axis represents the fraction of patients alive, cumulative survival (Cum. Surv.), and the x-axis time in months. Censored patients are indicated with
a vertical bar.
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Table 3 Association of clinical and genetic parameters with overall survival in the discovery cohort
Parameter n P-value HR
Age >50 years 23/98 0.187 1.57 (0.80-3.07)
Pre-operative KPS score <80 5/83 0.101 2.42 (0.79-7.05)
Pre-operative use of steroids 18/85 0.068 1.84 (0.99-3.58)
Pre-operative mass effect 37/71 0.0008 3.31 (1.61-6.73)
Pre-operative enhancement 35/79 0.031 2.16 (1.05-4.43)
Partial resection 69/90 0.029 2.85 (1.19-7.47)
Oligodendroglial histology 42/98 0.016 0.47 (0.25-0.87)
IDH1 or IDH2 mutation 86/97 0.071 0.47 (0.21-1.07)
1p/19q co-deletion without 10q loss 41/98 0.0001 0.30 (0.15-0.58)
Loss of 10q without 1p/19q co-deletion 15/98 0.001 2.91 (1.53-5.55)
Results were determined using a log rank test. n, patients in subgroup compared with total number of patients with available data for each parameter; HR, hazard
ratio (95% confidence interval). KPS, Karnofsky Performance Score.
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the 0-line than for the losses in 1p, 4, or 19q (Figure 4A)
[12]. Assuming clonality of the 1p/19q co-deletion [13],
this difference in extent of copy number loss suggests that
10q loss would only be present in about 30 to 35% of the
tumor cells (Figure S3 in Additional file 1).
To further delineate intratumoral heterogeneity of
CNAs in this sample, the originally outlined area was di-
vided into three sub-regions and an additional tumor re-
gion within the same paraffin section was included
(Figure 4B). The 1p/19q co-deletion as well as chromo-
some 4 loss were present in all sub-regions and
assumed to be clonally present. Losses of chromosomes
9, 10, 13, 15, 18 and gain of chromosome 11 were
present in one or few sub-regions and assumed to be
heterogeneously present (Figure 4C). To technically
validate the intratumoral copy number heterogeneity
observed in LGG240, array CGH was performed for all
but one (insufficient amount of DNA) of the spatially
distinct regions, which confirmed either clonality of
1p/19q and chromosome 4 losses or heterogeneity of
all six chromosomally aberrant regions (Figure S4 in
Additional file 1). Three additional samples with a
clonal type of deflection and four with a marginal de-
flection of (distal) 10q were technically validated by
array CGH (Figure S2 in Additional file 1). Intratu-
moral heterogeneity was detected in 15 out of 17 LGGs
analyzed for this purpose; 68% of the CNAs (84/124)
were not homogeneously present in spatially distinct
regions obtained during the same surgery, such as loss
of chromosomal arm 5q, chromosome 13 and gain of
11p (Figure 5A). Co-deletion of 1p and 19q was the
only CNA that was consistently present in all spatially
distinct regions of LGGs with this combination of
CNAs; others, such as gain of chromosomal arm 7q,
were most often, but not always, clonal. Loss of 10q
was heterogeneously present in seven out of eightpatients (Figure 5B). Histological variability did not
correspond to the extent of heterogeneity.
Temporal evolution of CNAs in LGGs
Forty-seven out of 98 patients were subjected to a second
surgery because of tumor progression. Of 20 patients, 24
recurrent tumors could be retrieved from medical ar-
chives. Almost 50% of CNAs (99/207) in the initial and
paired recurrent tumors were shared and 15% (31/207)
were uniquely detected in the initial tumor. A substantial
proportion (37%, 77/207) of CNAs was uniquely identified
in the recurrent tumor, such as loss of genomic regions at
chromosomes 4, 10 and 15 (Figures 5C and 6). 1p/19q
co-deletion was consistently identified in initial as well as
recurrent tumors and there were no cases with new
1p/19q co-deletion. In four patients, de novo loss of
10q (including distal 10q losses) surfaced in the recur-
rence. In hindsight, marginal deflection of 10q was ob-
served in the initial tumor of one of these four patients,
and was not detected by the calling algorithm [12]. In
two out of four patients with new loss of 10q a higher
malignancy grade (WHO grade III or IV) had been
assigned to the recurrent tumor (Figure 5D). In one of
the three patients for which both spatially distinct re-
gions of the initial tumor and recurrences were ana-
lyzed, subclonal 10q loss was present in one of the
regions of the initial tumor, but undetectable in the re-
currence (Additional file 3). In the other two patients,
10q loss was detected in both the initial and paired re-
current tumor.
Discussion
Intratumoral heterogeneity at the genomic level has been
observed in numerous types of cancer, although its impli-
cations for treatment often remain undetermined. In the
present study, archival LGG material and matched clinical
data provide insight into spatial and temporal evolution of
Figure 4 (See legend on next page.)
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Figure 4 Chromosomal copy number profiles for sample 240 demonstrating intratumoral copy number heterogeneity. (A) CNA profile
of initial tumor, clonal 1p/19q co-deletion, loss of chromosome 4 and intermediate level of loss of chromosome 10. (B) Hematoxylin and eosin
stained slide showing regions used for DNA isolation: the red dotted line corresponds to the region used for chromosomal profile of 4A and
regions outlined with a solid black line (labeled i to iv) were used for the chromosomal profiles of 4C. (C) CNA profiles from four non-overlapping
regions. Insets at the top right corner of each profile show histological features representative for individual regions. In all regions the histopathological
diagnosis was LGG, although within a tumor the regions analyzed for spatial heterogeneity often showed some variation in microscopic features, such
as cellularity and nuclear size and shape. (i) Clonal 1p/19q co-deletion and loss of chromosome 4; (ii) clonal 1p/19q co-deletion, loss of chromosome 4
and intermediate loss of chromosome 10; (iii) clonal 1p/19q co-deletion, loss of chromosome 4, intermediate loss of chromosome 10 and intermediate
gain of chromosome 11; (iv) clonal 1p/19q co-deletion, intermediate loss of chromosomes 4, 10q, 13, 15 and 18. The y-axis represents normalized log2
sequence read counts per bin, and the x-axis represents 15 kb bins ordered by genomic position from chromosomes 1 to 22.
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Figure 5 Spatial and temporal evolution of CNAs in LGGs and paired recurrent tumors. (A) CNAs in spatially distinct regions of LGGs of 17
patients. CNAs are categorized by detection in all regions (left panel), more than one region but not all regions (middle), or one region (right).
Patients are ordered by the number of regions analyzed of each LGG from high to low. (B) Summary of prognostically relevant CNAs in spatially
distinct regions and histology. No intratumoral heterogeneity was observed for 1p/19q co-deletion in any of the tumors, while distal 10q loss was
often only detected in subclones. OII, oligodendroglioma; AII, astrocytoma; OAII, oligoastrocytoma. (C) CNAs in initial and paired recurrent tumors
of 20 patients. CNAs are categorized by detection in initial tumor only (left panel), both initial and recurrence (middle) or detection uniquely in
the recurrence (right). Patients are ordered by the histological malignancy grade of the recurrent tumor. (D) Summary of prognostically relevant
CNAs in paired initial and recurrent tumors. 1p/19q co-deletion is stable over time, while distal 10q loss surfaces in recurrences, including two
with a higher malignancy grade than LGG. Patients are color-coded on the x-axis and chromosomes are ordered on the y-axis, 1 to 22 from
bottom to top. Shades of green enable visualization of individual chromosomal arms, their size varying by the number of regions. Hence, a
chromosomal arm with many breakpoints based on CNAs is depicted as larger compared with one with fewer breakpoints. CNAs smaller than 5
Mbp were excluded from this figure. Red, copy number loss; blue, copy number gain; black, no CNA. The arrowhead indicates patient 240, the
black squares three LGGs analyzed for both spatial and temporal evolution.
van Thuijl et al. Genome Biology 2014, 15:471 Page 8 of 13
http://genomebiology.com/2014/15/9/471
100% 
0%
100%
100% 
0%
100% B
A
chromosomes
1 2 4 5 6 7 10 12 15 223 18
initial tumors
recurrences
initial tumors
recurrences
Figure 6 CNAs in initial and recurrent tumors. (A) Gains; (B) losses. The top of each graph shows the initial tumors, and the bottom the
recurrences. Partial loss of chromosomal arm 4q, 9p and 10q were more frequently detected in recurrences. Bins are ordered by genomic
position and from chromosomes 1 to 22 on the x-axis; percentages of cases showing CNAs are depicted on the y-axis.
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for this study were included for copy number profiling by
shallow WGS combined with a depth of coverage ap-
proach, yielding high quality data without technical drop-
outs. This approach proved to be particularly beneficial
for our study, since no matched normal DNA is required,
which is a major advantage when analyzing long-term ar-
chived FFPE tumor samples. While shallow WGS cannot
detect copy-neutral loss of heterozygosity or rearrange-
ments, it is cost-effective, with a quality comparable to
array CGH and applicable to DNA isolated from the FFPE
samples. This allowed us to include samples that had been
archived for over 30 years and collate a representative co-
hort, including LGG patients with long survival.
The relatively low incidence of LGGs and relatively long
overall survival of patients necessitated this retrospective,
multi-center approach. The observed variability in post-
operative treatment can be attributed to the lack of a
standard of treatment for these patients. Despite these
variations, distal 10q loss (including whole chromosome
losses) was significantly associated with an unfavorable
prognosis in the discovery, validation and confirmation
cohorts. Previously, some studies with smaller cohorts
of specific histological subgroups of LGG have reported
a correlation between 10q and survival [6,7]. Further-
more, a high prevalence of whole chromosome 10 loss
and strong negative correlation with survival have been
reported for grade III and IV gliomas [14-17]. Partial
loss of 10q is much more frequently detected in histo-
logical grade II diffuse gliomas compared with grade III
and IV gliomas. In each of the previously published
studies the whole of chromosome 10 or the entire 10q
arm was taken into account. Here we demonstrate that,
different from higher grade gliomas, the distal end of10q is frequently lost and associates with overall sur-
vival in three cohorts. Spatial as well as temporal ana-
lyses suggest that subclones with distal loss of 10q are
involved in tumor progression, since the loss surfaces
in paired recurrent tumors with a higher malignancy
grade.
Identification of the genes and their proteins affected
by CNAs may elucidate the biological underpinnings of
their clinical relevance but can be challenging, especially
when a genomic region is large. Only after many years
were mutations in CIC and FUBP1 associated with co-
deletion of chromosomal arms 1p and 19q [18,19]. In
total 148 genes are located on 10q25.2-qter, including
MGMT, DMBT1 and ERCC6 [16,20,21], while the usual
suspect, PTEN, is located more proximal to the centro-
mere [16] and is preferentially lost in higher grade gli-
omas [4].
Based on our findings, we suggest that patients with
an LGG should be simultaneously tested for both 1p/19q
co-deletion and distal loss of 10q, since these two phe-
nomena seem to have counteractive effects on survival.
Introduction of heterogeneous CNAs, such as distal 10q
loss, in daily clinical practice requires a robust diagnostic
test. The well-known clonal features of 1p/19q co-deletion
have been helpful to interpret these intermediate copy
number levels in LGGs [13]. Analysis of multiple spatially
distinct regions could reveal subclones. We currently favor
genome-wide analysis, which visualizes chromosomes 1p,
distal 10q and 19q simultaneously, and at the same time
may provide insight into intratumoral heterogeneity
within one region. Both extent of resection as well as
the subclonal character of important markers for progres-
sion command alternative diagnostic procedures to assess
their presence in a postsurgical situation, which may in
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[4]. Meanwhile, detailed registration of the positions of
samples from different regions within a tumor obtained
during the same surgery may provide more accurate
insight into biologically relevant topics such as the
physical distance and direction of growth of tumor sub-
clones as well as the overall extent of heterogeneity of a
tumor [22].
Conclusions
Copy number analysis by shallow WGS is a robust ap-
proach for archival clinical LGG specimens. For a large
proportion of LGG patients, analysis of CNAs with
prognostic value may improve personalized timing of
therapy. Thereby, loss of distal 10q without 1p/19q co-
deletion is indicative for urgent postoperative treatment,
while in LGGs without loss of 10q and with 1p/19q co-
deletion a wait-and-scan policy should be considered.
The subclonal character of whole or distal 10q loss in a
subset of samples emphasizes the need for maximal extent
of resection, illustrates that single sample diagnostics may
be insufficient for LGG and favors future studies on
genome-wide analysis of multiple spatially distinct sam-
ples to map tumor progression.
Materials and methods
Clinical data and sample collection for discovery,
validation and confirmation cohorts
Approval for collection of clinical data and FFPE tumor
samples for the 98 patients of the discovery cohort was
obtained from the institutional review boards of all five
Dutch hospitals, namely the Medical Ethical Committee
(in Dutch: Medisch-Ethische Toetsingsingscommissie or
METc) of the Academical Medical Center (AMC), the
METc of the Isala klinieken in Zwolle, the METc of the
VU University Medical Center (VUmc) in Amsterdam,
the METc of the St Elisabeth Hospital in Tilburg, and
the METc of the Arnhem - Nijmegen Region for samples
from Radboud University Medical Center in Nijmegen
(CMO). Experimental methods in this manuscript are in
compliance with the Helsinki Declaration. Inclusion cri-
teria and characteristics of the discovery cohort are sum-
marized in Figure 1 and Table 1. Clinical features of the
validation cohort, from a French hospital, can be found
in Table 1; materials and methods are presented in more
detail by Alentorn et al. [5]. For the confirmation cohort,
copy number data of 531 lower grade glioma patients
from the TCGA database were downloaded on 12 June
2014 via the Cancer Browser at UCSC [23]. Clinical data
were available for 373 of these patients, including grade
and overall survival; 184 of these samples were catego-
rized as ‘diffuse glioma histological grade 2’ and selected
as a confirmation cohort [10]. Presumably as a conse-
quence of the fact that only fresh frozen samples wereincluded in the TCGA cohort, a limited number of pa-
tients are contained in the dataset that had deceased
during follow-up.
Laboratory techniques
Histological revision of samples in the discovery cohort
was performed by two experienced neuropathologists
(EA and PW). For all samples in the discovery cohort, in-
cluding paired recurrent tumors, areas containing >60%
tumor cells were outlined on hematoxylin and eosin
stained slides, and tumor cell percentage estimated and
registered for each sample (Additional files 2 and 3 and
Table S1 in Additional file 4) and 10 adjacent sections
were used for DNA isolation [24]. For the assessment of
intratumoral heterogeneity, spatially distinct regions
were selected based on histological variability and/or
plain physical distance (Additional file 4). These samples
were obtained either from one FFPE block, or individual
blocks from the same surgery (Table S1 in Additional file 4).
DNA (500 ng) was fragmented by sonication (Covaris™
S2, Woburn, MA, USA), and sequenced using a 50 bp
single-read (50 bp SR) modus (Illumina TruSeq DNA-
kit and HiSeq 2000, San Diego, CA, USA). The 100 bp
paired-end (100 bp PE) sequencing modus and array
CGH were used for comparison and technical validation.
Array CGH was performed as described previously [25].
IDH1 and IDH2 mutation analysis was performed as de-
scribed previously [5].
Statistical analysis
Copy number data from shallow WGS were analyzed
using a novel Bioconductor script called QDNAseq [26].
QDNAseq infers copy numbers through depth of coverage
by binning reads uniquely aligned to the human reference
genome build GRCh37/hg19 with Burrow’s Wheeler
Alignment (BWA) [27]. PCR duplicates and reads with
mapping qualities below 37 (highest value returned by
BWA) were filtered. Copy numbers were inferred from
the number of sequence reads per 15 kb bin. A simul-
taneous Loess correction for sequence mappability and
GC content is applied within QDNAseq, which reduces
noise of the copy number profiles, particularly for those
with more degraded DNA. Problematic genome regions
were furthermore filtered by applying our procedures to
sequence data from the 1000 Genomes Project [28] to ob-
tain a blacklist that eliminates problematic regions and the
most common copy number variants of germ-line origin.
Sequence data as well as all array CGH data have been
uploaded to the European Genome-phenome Archive
(EGA; accession number EGAS00001000643).
Calling of CNAs into discreet categories (normal, gain
or loss) for the discovery and validation set was per-
formed with the Bioconductor/R-package CGHcall
[12]. A weighted hierarchical clustering of the CNAs
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ity of chromosomal profiles [29]. Association with sur-
vival was tested using a log rank test with significance
estimated over 10,000 permutations. After discovery of
regions of interest for survival, consecutive regions in
the same chromosome with P-values <0.05 were fused
together to final regions and the log rank test was re-
peated. Chromosomal regions that were still significant
in the discovery set after multiple testing correction ac-
cording to Benjamini-Hochberg were verified in the inde-
pendent French validation cohort. Therefore, genomic
coordinates were converted to the NCBI35/hg17 genome
build using the UCSC liftOver tool [30] and P-values were
calculated with the log rank test and adjusted with the
more stringent Holm-Bonferroni method. The statistical
significance of a CNA was calculated compared to the
rest of the cohort not bearing this CNA - for example,
samples with loss of distal 10q versus samples without
loss of distal 10q.
Regions significant in both the discovery and validation
cohorts were tested in the TCGA confirmation cohort for
which CNA data were generated with Affymetrix SNP 6.0
arrays (Santa Clara, CA, USA). TCGA level 3 copy num-
ber data were publicly available at the time of download
and mapped to NCBI36/hg18. These level 3 data involve
beginning and end positions of chromosomal segments
with deflection values, resulting from TCGA preprocessing
(for level definitions and preprocessing see [31]). Segment
values were converted to CNA discreet categories by setting
thresholds whereby a log2 ratio of >0.20 is gain, < -0.23
is loss and all other values are normal copy number;
these values correspond to 30% of the tumor cells with
that CNA. Those segments overlapping for at least 90%
of the 1p, 19q (excluding centromeres) or 10q25.2-qter
region (corresponding to NCBI35/hg17: chr10: 112939991-
135323881 and NCBI36/hg18: chr10:112939991-135284990)
were taken into consideration. At this setting 14 patients
had a distal 10q loss, of which 4 deceased during follow-
up and no patients had both distal 10q and 1p/19q loss.
P-value calculations were performed as described above
without corrections since only one region was tested for
confirmation. The threshold settings were selected
based on the fact that a deletion in 30% of the tumor
cells, as observed for the chromosome 10 loss in LGG
sample 240 (Figure S3 in Additional file 1), should not
be missed. All other threshold values for calling losses
of these regions were stepwise tested as well as the per-
centage of overlap with the 10q25.2-qter region and are
presented in Table S2 in Additional file 4. Significance
for the 10q loss remained for many different settings,
but the number of patients with this loss substantially
decreased with widening margins for calling CNAs to
lower than should be expected based on the discovery
and validation cohorts.To assess the presence of CNAs between spatially distinct
regions and/or recurrences from the same patient, common
regions were detected with CGHregions [32], and regions
smaller than 5 Mbp were excluded. Clinical parameters
were analyzed with log rank test. All reported P-values were
two-sided, and <0.05 was considered statistically significant.
Data availability
Both array CGH and sequence data have been uploaded
to the European Genome-phenome Archive (EGA; ac-
cession number EGAS00001000643).Additional files
Additional file 1: Figure S1. Evaluation of shallow WGS for genome-wide
copy number analysis for read lengths of sample LGG 284. Copy number
profiles were produced by counting the number of uniquely mapped
sequence tags per 15 kb bin for different settings. (A) Paired-end 100
(PE100), 100 bp reads from both ends. (B) Single-end 100 (SR100),
100 bp reads. (C) Single-end 50 (SR50), 50 bp reads from one end.
(D) Technical validation by array CGH of the same sample. Y-axis, normalized
log 2 sequence read counts per bin; x-axis, 15 kb bins ordered by genomic
position from chromosomes 1 to22. Figure S2. Technical validation of shallow
WGS by array CGH CNA analysis of eight LGGs tested on both platforms.
The level of deflection of CNAs was comparable. Also, heterogeneously
present CNAs with only marginal deflection could be reproduced; LGGs
168, 184 and 193 show clonal distal 10q loss, while LGGs 187, 189, 210,
211 and 224 show subclonal loss of 10q. Figure S3. Minimal tumor cell
percentage required for detection of CNAs. Calculation of the percentage of
tumor cells with a chromosome 10 deletion in LGG240. To simulate a limited
tumor percentage, a virtual tumor-normal mixture experiment was performed
with LGG240 (diffuse low-grade glioma) and NA18960 ((1000 Genomes Project
Consortium). Figure S4. Technical validation of shallow WGS by array CGH.
Technical validation of LGG240 (original) and three spatially distinct regions.
Additional file 2: Copy number profiles generated with shallow WGS
of original LGGs of the discovery cohort and spatially distinct regions
of this tumor obtained during the same surgery. A representative
picture of histology (hematoxylin and eosin staining, original
magnification × 200) is depicted in the top left corner of each profile.
Additional file 3: Copy number profiles generated with shallow
WGS of initial LGGs and paired recurrent tumors. A representative
picture of histology (hematoxylin and eosin staining, original
magnification × 200) is depicted in the top left corner of each profile.
Additional file 4: Table S1. Overview of all samples of the discovery
cohort, including paired recurrent tumors and spatially distinct regions.
Columns show ID number, relative spatial distance (one FFPE block or
individual FFPE block), histology, prognostically relevant CNAs, distal 10q
loss, 1p/19q co-deletion, read count, sequence depth and tumor cell
percentage as estimated by neuropathologists. Table S2A-C. Matrix with
P-values for overall survival of the TCGA LGG (grade 2) confirmation
cohort at various thresholds. Vertical rows: log2 ratio thresholds for calling
CNA discrete categories (loss, normal or gain) from the log2 ratio level 3
data downloaded from the Cancer Browser at UCSC [23]. Horizontal rows:
thresholds for overlap with the 10q25.2-qter region. Grey, non-significant
settings; shades of beige, significant settings (darker indicates higher
signioficance); bold, threshold settings used for Figure 3. (A) P-values
rounded to four decimal places for samples with or without a distal
chromosome 10q loss. (B) Number of grade 2 LGG patients with clinical
data (n =184) from the lower grade glioma TCGA dataset with a distal
10q deletion. (C) Number of grade 2 LGG patients (n =184) from the lower
grade glioma TCGA dataset with a distal 10q deletion that had deceased
during follow-up. Overall survival is significant for various settings of distal
10q loss. The number of patients with distal 10q loss substantially decreased
with widening margins for calling CNAs, to lower than should be expected
based on the French and Dutch cohorts.
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